ACADIA Pharmaceuticals(ACAD) - 2023 Q4 - Annual Results

Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview - 2023 total net product sales of $726.4 million, reflecting 40% revenue growth. - Fourth quarter DAYBUE™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $143.9 million and full year 2023 net product sales of $549.2 million. SAN DIEGO, CA, February 27, 2024 – Acadia Pharma ...